Zealand Pharma


Date of Award

05.07.2015

Program

Type 1 Diabetes, Improve Outcomes

Amount

$1,833,000

Term of Grant

18 months

Project Title

Safety evaluation of chronic and sub-chronic use of the glucagon analogue ZP4207 for the treatment of hypoglycemia

Project Description

Funding to augment Zealand Pharma’s efforts to expand the safety studies of a novel stable glucagon analog, ZP4207, to allow the analog be used chronically for various indications aimed at improving health outcomes for people with type 1 diabetes.